Oncology

Women with hereditary cancer syndromes face complex decisions that weigh the benefits of ovarian cancer prevention against the potential long-term risks of cardiovascular disease.

Colonic stenting for obstructing colorectal cancer can be performed with acceptable radiation exposure while offering patients a strong chance of avoiding stoma formation, according to new findings.

Invasive gastric cancer may develop in distinct patterns after eradication of Helicobacter pylori, with endoscopic surveillance revealing unique clinical characteristics compared to intramucosal gastric cancers.

Advances in early detection, prevention, and treatment are reshaping the outlook for pancreatic cancer, one of the deadliest malignancies worldwide.

Patients with unresectable pancreatic cancer who receive second-line treatment with nanoliposomal irinotecan in combination with fluorouracil and folinic acid may remain eligible for subsequent third-line chemotherapy.

Clinical cancer research across the Asia-Pacific region faces substantial barriers, with competing demands, lack of funding, and limited infrastructure emerging as the most significant obstacles, according to a large cross-sectional survey of healthcare professionals.

Machine learning can help predict urgent care visits in patients with non–small cell lung cancer receiving systemic therapy.

Long-term head and neck cancer survivors frequently report poor oral health-related quality of life, with persistent late toxicities remaining common more than 8 years after diagnosis.

AI is rapidly transforming oncology, but many clinicians lack practical tools to evaluate its real-world reliability.

Acute diarrhea during chemoradiotherapy for anal cancer is significantly more likely among patients treated with 5-fluorouracil (5-FU) or capecitabine compared with those receiving cisplatin or radiotherapy alone, according to new findings.

Overall survival in the Asia cohort of the Phase III MARIPOSA study has been reported to favor amivantamab combined with lazertinib compared with osimertinib monotherapy in patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).

Timely initiation of postoperative radiation therapy (PORT) within 6 weeks of surgery is a critical factor in improving outcomes for patients with head and neck squamous cell carcinoma.

Ocular toxicities are an emerging challenge in the management of gynecologic cancers treated with antibody drug conjugates, with new research outlining prevention and care strategies to safeguard patient outcomes.

A new real-world study has mapped the treatment landscape for mantle cell lymphoma (MCL) in Japan, highlighting common patient characteristics, therapeutic strategies, and ongoing gaps in efficacy and quality of life outcomes.

Confirmatory testing for men with low-risk prostate cancer increased steadily in recent years, but a payment incentive program was not linked to a statistically significant improvement in its use, according to a large cohort study.

Greater familiarity among surgical teams significantly improves outcomes in renal, bladder, and prostate cancer procedures, according to a new study assessing team membership and cohesion.

TAR-200, an investigational intravesical drug-releasing system delivering sustained gemcitabine, demonstrated high response rates and durable outcomes in patients with bacillus Calmette-Guérin (BCG)–unresponsive high-risk non–muscle-invasive bladder cancer (NMIBC), according to results from the Phase IIb SunRISe-1 study.

Patients with chronic lymphocytic leukemia (CLL) who consistently saw the same oncologist or hematologist experienced significantly fewer emergency room visits and hospitalizations, according to a large real-world study of nearly 6,000 individuals treated with covalent Bruton tyrosine kinase inhibitor (cBTKi) therapy.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), widely used for diabetes and weight reduction, may offer significant benefits in improving outcomes for patients with non-small cell lung cancer (NSCLC), according to new clinical and preclinical evidence.

Immunotherapy combined with standard neoadjuvant chemotherapy has shown encouraging benefits in hormone receptor positive, HER2 negative early breast cancer, according to new evidence.

The addition of nivolumab to platinum-etoposide chemotherapy improved both progression-free and overall survival in patients with extensive-stage small cell lung cancer (ES-SCLC), according to results from the randomized Phase II ECOG-ACRIN EA5161 trial.

Frequent ibuprofen use was associated with a reduced risk of endometrial cancer, while aspirin showed no measurable effect, according to a large cohort analysis of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.

Pediatric central nervous system (CNS) tumors remain among the most fatal childhood cancers, largely because the blood-brain barrier (BBB) restricts effective therapeutic delivery and worsens clinical outcomes.

A Phase I trial of a pancreatic cancer vaccine targeting mutant KRAS has demonstrated durable immune responses and promising survival outcomes in patients with minimal residual disease following standard treatment.

A large population-based case–control study has found that a history of malignant melanoma (MM) does not increase the likelihood of developing vitiligo in the general population, with a notable exception in the Arab minority.

Patients with psoriasis initiating biologic therapy, particularly tumor necrosis factor (TNF) inhibitors, may have a reduced long-term risk of developing primary malignancies compared with biologic-naïve individuals, according to a large retrospective cohort study.

Interstitial lung disease (ILD) is independently associated with a significantly higher risk of developing lung cancer, according to new findings from a large population-based cohort study that controlled for genetic factors.

Robotic-assisted techniques could one day enhance the precision of Mohs micrographic surgery (MMS) for rare cutaneous sarcomas such as dermatofibrosarcoma protuberans (DFSP), but current technology remains ill-suited for skin-level applications, according to recent research.

Chimeric antigen receptor (CAR) immunotherapies are rapidly advancing beyond hematologic cancers, with new generations of CAR constructs and immune cell platforms showing promise across a wide spectrum of diseases.

Lung transplantation can be safely performed in men with newly diagnosed, localized high-risk prostate cancer prior to definitive cancer treatment, according to a new case review.

Sexual well-being of spouses of patients with colorectal cancer living with an ostomy is significantly impacted, with new research highlighting a critical gap in supportive care that fails to consider the emotional and intimate needs of partners.

The bladder microbiomes of women diagnosed with gynecologic cancer are strikingly similar to those of women without such a diagnosis, according to new research.

A groundbreaking study has leveraged novel machine learning algorithms to predict the five-year postoperative survival of patients with Stage III colorectal cancer (CRC), providing healthcare professionals with a powerful tool for personalized treatment planning.

A pilot study has revealed promising results for blue light photobiomodulation in treating complicated postsurgical breast wounds, with significant improvements in healing times and reduced complication severity.

Obese women who spend extended hours sitting each day may face an increased risk of developing breast cancer, according to a recent nationwide study.

In a groundbreaking study evaluating intraoperative radiotherapy (IORT) as a tumor bed boost with whole-breast irradiation (WBI) for patients with breast cancer undergoing breast-conserving surgery (BCS), researchers found that the combination approach offers promising safety and efficacy outcomes.

A pilot study using indocyanine green lymphography (ICG-L) has provided new insight into how head and neck cancer (HNC) treatments disrupt lymphatic drainage and contribute to lymphoedema, highlighting an often-overlooked source of physical and neurological symptom burden among survivors.

A new survey reveals that nearly half of patients receiving radiation therapy for cancer are open to exploring psychedelic-assisted therapy, spotlighting a growing curiosity about novel approaches to managing cancer-related distress.

Anal cancer screening in people with HIV (PWH) is entering a new era, following major advances in evidence and recent guideline updates that aim to reduce cancer burden in this high-risk group.

Immune checkpoint inhibitors (ICIs) have transformed cancer care but can trigger immune-related adverse events such as psoriasis, complicating treatment decisions.

A novel deep learning approach to body composition analysis may offer a cost-effective and clinically relevant method to predict treatment outcomes in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), according to findings from the LOTIS-2 trial.

The use of beta-blockers has dramatically changed the management of infantile hemangiomas, with a significant increase in active treatment decisions at tertiary referral centers, according to a new retrospective cohort study.

Subcutaneous (SC) delivery of immunotherapies for solid tumors has emerged as a potentially transformative approach to cancer treatment, promising comparable clinical efficacy to intravenous (IV) therapies while significantly reducing treatment time and burden on healthcare systems.

An artificial intelligence tool trained on digital pathology slides has demonstrated clinical-grade accuracy for detecting EGFR mutations in lung adenocarcinoma and significantly reduced reliance on molecular testing, according to results from a large-scale real-world deployment study.

Modulating the gut microbiome may enhance immunotherapy responses in patients with solid tumors, according to a recent review exploring emerging evidence across melanoma, renal cell carcinoma (RCC), and non-small cell lung cancer (NSCLC).

Disparities in the use of patient portal messaging remain prevalent among oncology patients, even among those who are already enrolled, according to a large retrospective study from an urban academic cancer center.

Sexual health problems are highly prevalent and distressing among breast cancer survivors, yet the majority of women report receiving little to no support from their healthcare teams, according to findings from the WISH-BREAST survey.

A nationwide study of basal cell carcinoma (BCC) excisions in Denmark found that hospital-based specialists have significantly lower odds of incomplete removal than their practice-based peers, raising important questions about treatment setting and provider expertise.

A 15-year retrospective study from southeastern Romania has revealed a high mortality burden associated with HIV-related lymphomas, underscoring the critical need for earlier diagnosis and integrated treatment strategies.

Metformin use linked to significantly lower colorectal cancer risk in patients with inflammatory bowel disease, according to a new population-based cohort study.

A new randomized study finds that integrating breast density and polygenic risk scores (PRS) into breast cancer risk assessments significantly alters individual risk estimates and may influence future screening strategies.

Post-treatment MRI frequently underestimates tumor size in patients with invasive lobular carcinoma (ILC) who receive neoadjuvant therapy, according to new findings that may influence surgical planning in this breast cancer subtype.

Multimodal psychological interventions such as yoga, relaxation, and meditation may help reduce pain following breast cancer surgery, according to a new systematic review evaluating their effectiveness in survivorship care.

A digital integration strategy significantly improved coordination and data collection across multiple lung cancer screening sites, according to a new study evaluating implementation within a large U.S. health system.

A novel artificial intelligence pipeline can predict BRAF mutation status directly from histopathology slides, marking a potential step forward in digital dermatopathology and melanoma care.

A new study reveals significant gaps in follow-up care among survivors of adolescent and young adult (AYA)–onset cancers, with nearly one in five missing all oncology specialty visits during the surveillance period.

Trastuzumab deruxtecan combined with pertuzumab significantly delayed disease progression compared to standard care in patients with HER2-positive advanced breast cancer, according to initial findings from the DESTINY-Breast09 Phase III trial.

Breast cancer survivors may face a lower risk of Alzheimer’s disease than their cancer-free peers, according to a large retrospective cohort study examining long-term cognitive outcomes following treatment.

Pro-inflammatory diets may increase the risk of death in patients with Stage III colon cancer, according to a new analysis of dietary patterns in a large cohort of U.S. patients.

A randomized controlled trial has found that Bojungikgi-tang (BJT), a traditional East Asian herbal medicine, significantly improved symptoms of anorexia and atopic dermatitis (AD) while altering the gut microbiome in affected patients.

Switching to camizestrant upon detection of an ESR1 mutation, before clinical disease progression, may extend progression-free survival (PFS) for patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancer, according to results from the Phase III SERENA-6 trial.

As cancer therapies evolve and autoimmune diseases become more prevalent, the intersection of oncology and rheumatology, onco-rheumatology, is emerging as a critical field demanding transdisciplinary care.

Efforts to optimize treatment for Stage II testicular seminoma are intensifying, as new approaches aim to reduce long-term toxicity while preserving the high cure rates associated with standard therapies.

In a large retrospective study, percutaneous balloon dilation was found to have a statistically significant advantage over open reconstructive surgery for treating high-grade benign biliary strictures, especially those classified as Bismuth-Strasberg type E4 and E5, which are known for technical complexity and recurrence risk.

A gene-based assay may help guide adjuvant chemotherapy decisions in early-stage non-squamous non-small cell lung cancer (NSCLC), according to interim results from a randomized clinical trial presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.

Results from an international Phase III clinical trial presented at the 2025 ASCO Annual Meeting evaluate a treatment regimen combining encorafenib and cetuximab with mFOLFOX6 chemotherapy in patients with previously untreated BRAF V600E-mutant metastatic colorectal cancer (mCRC).

A new study exploring women’s body image after mastectomy sheds light on the complex emotional and psychosocial challenges these patients face during and after breast cancer treatment.

Adding nivolumab to postoperative chemoradiotherapy may reduce the likelihood of recurrence in patients with resected, high-risk head and neck squamous cell carcinoma (HNSCC), according to results from the Phase III NIVOPOSTOP trial presented at the 2025 ASCO Annual Meeting.

Patients with unresectable, locally advanced or metastatic PD-L1-positive triple-negative breast cancer (TNBC) experienced longer progression-free survival when treated with sacituzumab govitecan and pembrolizumab, compared to the current standard of chemotherapy plus pembrolizumab, according to new findings presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.

Second-line treatment with trastuzumab deruxtecan has been shown to extend overall survival by more than 3 months in patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma (GEJA) following progression on first-line therapy, according to Phase III data from the DESTINY-Gastric04 trial presented at the ASCO 2025 Annual Meeting.

First-line maintenance treatment with lurbinectedin and atezolizumab significantly improves survival outcomes in patients with extensive-stage small cell lung cancer (ES-SCLC), according to primary results from the global Phase III IMforte trial presented at ASCO 2025.

A NEW oral therapy may significantly delay disease progression in patients with ESR1-mutated, ER-positive, HER2-negative advanced breast cancer, according to results presented at the 2025 ASCO Annual Meeting.

A novel artificial intelligence (AI) framework called AutoRadAI has demonstrated strong diagnostic performance in detecting extracapsular extension (ECE) in prostate cancer, a key prognostic factor that can significantly impact treatment planning and surgical outcomes.

In the high-stakes landscape of cancer treatment where healthcare professionals rely on cost-effectiveness analyses to guide decisions adverse event costs may be throwing off the equation.

A new study sheds light on the hidden cardiovascular risks lurking in the critical first 100 days following allogeneic hematopoietic stem cell transplantation (HSCT).

Prostate cancer survivors face a long-term threat that often goes undetected, a third primary cancer, according to new findings that highlight an under-recognized but serious risk with significant survival implications.

A new national study published ahead of print in JCO Oncology Practice reveals a steady increase in time to treatment initiation (TTI) across all 30 of the most prevalent cancer types, with early-stage diagnoses now a major driver of these delays.

n a new 5-year follow-up study exploring diagnostic tools for adenocarcinoma of the esophagogastric junction (AEG), PET combined with MRI (PET/MRI) has shown strong potential for predicting long-term survival.

Cancer survivors face a significantly increased risk of cardiovascular mortality, according to a major nationwide study in Japan that highlights key differences in cardiovascular risk across cancer types and specific heart-related diseases.

At the 2025 AACR Annual Meeting, researchers unveiled an AI-driven model that significantly improves the early detection of cancer cachexia by analyzing routinely collected diagnostic imaging and clinical data.

Cancer-related fatigue and depression in survivors are strongly associated with a drop in recreational physical activities and overall quality of life, according to data presented at the American Association for Cancer Research (AACR) Annual Meeting 2025.

AI-based models analyzing digital pathology images may offer a major leap in pediatric sarcoma diagnosis accuracy, according to research presented at the American Association for Cancer Research Annual Meeting 2025.

Breast cancer mortality in women aged 20 to 49 has significantly declined across all racial and molecular subgroups, according to findings presented at the AACR Annual Meeting 2025 in Chicago, Illinois.

Patients with newly diagnosed, locally advanced head and neck squamous cell carcinoma (HNSCC) may soon benefit from a major shift in treatment strategy, as phase III trial data show that perioperative pembrolizumab significantly improves outcomes when added to standard care.

Promising new data emerged on zongertinib, an investigational oral therapy targeting HER2 mutations in advanced non-small cell lung cancer (NSCLC), was presented at the AACR Annual Meeting 2025 in Chicago.

At the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago, new data revealed that a liquid biopsy using circulating tumor DNA (ctDNA) could detect colorectal cancer recurrence significantly earlier than imaging, with ctDNA signals appearing up to 416 days before clinical detection.

At the AACR Annual Meeting 2025 in Chicago, researchers unveiled promising early results from a novel cell therapy that could reshape treatment options for patients with relapsed or refractory acute myeloid leukemia (AML).

Neoadjuvant immunotherapy using PD-1 blockade has demonstrated the potential to eliminate the need for surgery in patients with early-stage mismatch repair-deficient (dMMR) cancers, according to groundbreaking data presented at the AACR Annual Meeting 2025.

At the AACR 2025 Annual Meeting in Chicago, new data presented on the investigational agent zoldonrasib showed encouraging clinical activity in patients with non-small cell lung cancer (NSCLC) harboring the KRAS G12D mutation.

Timely lung cancer diagnosis and treatment are essential for improved survival, but new research shows that patients with suspicious lung nodules continue to experience critical delays at multiple stages of care.

Patients undergoing spinal surgery for metastatic disease face a heightened risk of nonroutine discharge, often leading to increased healthcare costs and higher readmission rates.

A recent study offers fresh insights into how heart rate variability (HRV) measures, both linear and nonlinear, can help detect autonomic nervous system dysfunction in fibromyalgia (FM), a chronic condition marked by widespread pain, fatigue, and mood disturbances.

In a real-world study examining neoadjuvant chemotherapy for human epidermal growth factor receptor 2-positive (HER2+) breast cancer, researchers have identified key predictors of treatment response and long-term survival, providing critical insights for oncologists managing this aggressive disease.

In a significant update for head and neck oncology care, new clinical insights into transoral robotic surgery (TORS) for oropharyngeal squamous cell carcinoma (OPC) aim to guide U.S. physicians in tailoring treatment plans through a multidisciplinary lens.

Sexual health after breast cancer remains one of the least addressed yet deeply impactful aspects of survivorship, according to a new qualitative study that gives voice to the intimate challenges faced by women in the aftermath of treatment.

Pediatric cancer care, medical tourism, and cross-border access to healthcare converge in a newly published 10-year review highlighting international families traveling to the United States for treatment of serious childhood malignancies and blood disorders.

Electronic patient-reported outcomes (ePROs) are increasingly seen as a promising tool to improve cancer care quality, especially for patients with metastatic disease.

A new systematic review sheds light on how prehabilitation, interventions initiated before treatment, may influence long-term physical function and patient-reported outcomes in people affected by bladder cancer.

In the treatment of relapsed/refractory multiple myeloma, CAR T-cell therapy using idecabtagene vicleucel (ide-cel) has demonstrated encouraging results in a large real-world U.S. patient cohort, according to new data from the CIBMTR registry.

A new study on superficial basal cell carcinoma treatment decisions highlights that patient decision aids may subtly shift treatment preferences, with keywords such as superficial basal cell carcinoma, patient decision aid, non-invasive treatment, and effective decision-making underscoring the research.

A major phase 3 lung cancer trial investigating the TGIT-targeting immunotherapy ociperlimab has been halted after interim analysis indicated it would not meet its primary endpoint of overall survival.

The rapid rise in prescriptions for GLP-1 receptor agonists, including tirzepatide (Mounjaro) and semaglutide (Ozempic; Lilly, Indianapolis, Indiana, USA), has sparked concerns about potential long-term safety risks.

Transportation barriers are a significant yet often overlooked challenge for patients with multiple myeloma (MM), affecting access to timely care and overall health outcomes.

Virtual reality (VR) is emerging as a powerful tool for enhancing cancer patient education, significantly improving understanding of disease and treatment, according to new research.

Discover how SITC’s innovative strategies are transforming clinical trials to accelerate the development and approval of cancer immunotherapies, aiming for 100 new treatments in the next decade.

Women experiencing housing insecurity are significantly less likely to receive routine breast cancer screening, according to a new study analyzing Medicaid beneficiaries in Pennsylvania.

The widespread overuse of adrenal CT scans, revealing that more than half of these imaging studies are performed unnecessarily, has been investigated in a new study.

A new post hoc analysis of the ADAURA trial highlights the role of osimertinib in detecting molecular residual disease (MRD) in resected EGFR-mutated stage IB–IIIA non-small-cell lung cancer (NSCLC).

Patients recovering from lung cancer surgery may face prolonged hospital stays when wildfires strike, according to new research examining the effects of wildfire disasters on post-operative recovery.

A deep learning model offering a powerful tool for predicting how patients with advanced non-small cell lung cancer (NSCLC) will respond to immune checkpoint inhibitors (ICIs), potentially improving treatment personalization, has been newly developed.

A phase II trial evaluating the combination of pembrolizumab and bevacizumab in patients with untreated melanoma brain metastases (MBM) has demonstrated substantial clinical activity and promising survival outcomes.

In a pivotal development for the oncology community, a recent retrospective study has demonstrated that continuing immunotherapy beyond disease progression offers significant survival benefits for patients with advanced non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).

A recent study reveals a modest increase in early palliative care (PC) billing among Medicare beneficiaries diagnosed with distant-stage cancers from 2010 to 2019.

In Southeastern Michigan, Black men face disproportionately higher mortality rates from prostate cancer, often presenting with more advanced disease stages.

A recent study has revealed that adult survivors of childhood cancer face a significantly elevated risk of developing melanoma, underscoring the necessity for vigilant long-term monitoring and tailored preventive strategies.

A recent cohort study has highlighted significant disparities in comorbidity profiles among patients undergoing low-dose computed tomography (LDCT) for lung cancer screening.

Integrative sleep medicine is revolutionizing cancer care, as highlighted at the 21st Annual Miami Cancer Meeting (MCM) in Tampa, Florida, this January.

Early-onset breast cancer incidence in the U.S. is rising, but new research suggests the increase is not uniform across all states. A recent study analyzing trends from 2001 to 2020 found that breast cancer rates in women under 40 have increased significantly in 21 states, with distinct regional differences.

A long-term study of assisted reproductive technology (ART) has found no increased risk of endometrial cancer, addressing concerns about the potential long-term effects of fertility treatments.

A new treatment combination has emerged for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who are ineligible for autologous stem cell transplant (ASCT).

18F-FDG PET and PET/CT scans show strong diagnostic accuracy in detecting histological transformations (HT) in indolent lymphomas, including Richter’s transformation (RT) in chronic lymphocytic leukemia (CLL), according to a new meta-analysis.

A machine learning model, SCORPIO, has shown promise in predicting the success of immune checkpoint inhibitors (ICIs) for patients with cancer.

A recent prospective cohort study highlights the incidence and clinical course of abemaciclib-induced interstitial lung disease (ILD) in patients with hormone receptor-positive (HR+), HER2-negative metastatic breast cancer (MBC) previously treated with chemotherapy.

A new study has found that diet may play a key role in survival for women diagnosed with early-stage ovarian cancer.

The power of explainable artificial intelligence (xAI) combined with multimodal real-world data (RWD) to improve cancer prognosis across multiple cancer types was explored in a new study.

A new treatment for limited-stage small cell lung cancer (LS-SCLC) has been recommended for approval in the European Union following positive results from a Phase III trial.

In the battle against lung cancer, a recent editorial examines the effectiveness of risk prediction models in determining screening eligibility.

Lung cancer remains one of the deadliest diseases worldwide, with changing risk factors influencing mortality rates.

A recent multicenter Phase II trial has demonstrated that combining chemoradiotherapy (CRT) with aggressive local consolidative therapy (LCT) can improve survival rates in patients with Stage IV non-small cell lung carcinoma (NSCLC) presenting with oligometastases.

A Phase II trial examining neoadjuvant therapy for difficult-to-resect cutaneous basal cell carcinoma (BCC) demonstrates promising outcomes.

Immune checkpoint inhibitors, widely used in cancer therapy, have revolutionized oncology but come with the risk of severe immune-related adverse events, including checkpoint myocarditis.

A groundbreaking study has revealed that white button mushrooms (WBM) may reduce immune suppression and enhance anti-cancer immune responses in patients with prostate cancer.

Colorectal cancer (CRC) screening guidelines may need to be more tailored, according to new research that identifies optimal stopping ages for screening based on sex, comorbidity status, and prior screening history.

The U.S. Food and Drug Administration (FDA) approved a novel combination therapy for adults with KRAS G12C-mutated metastatic colorectal cancer (mCRC).

A new study has unveiled a groundbreaking cancer treatment approach using engineered extracellular vesicles to target both tumor cells and immunosuppressive stromal cells in the tumor microenvironment (TME).

A recent observational study has shown that AI can significantly enhance breast cancer detection rates in mammography screening without increasing unnecessary recalls.

Post-transplant care has demonstrated that collaboration between hematopoietic cell transplantation (HCT) specialists and local oncologists can safely enhance patient outcomes while reducing caregiver burdens in a recently published research article.

A Phase III clinical trial, ECHELON-3, has demonstrated survival benefits for patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) using a combination therapy of brentuximab vedotin (BV), lenalidomide (Len), and rituximab (R).

Significant advancements in tailoring salvage therapy for pediatric patients with relapsed or refractory classic Hodgkin lymphoma (cHL) have been revealed in a recent clinical trial.

A recent study has unveiled a mechanism by which estrogen receptor-positive (ER+) breast cancer cells become more aggressive after spreading to the bone marrow.

A recent Phase I clinical trial has provided promising results for a novel immunotherapy approach to treat early-stage ERBB2-positive breast cancer.

A recent study suggests multi-ancestry polygenic risk scores (PRS) may help refine active surveillance strategies for low- to intermediate-risk prostate cancer.

Selpercatinib, a targeted RET kinase inhibitor, has demonstrated continued efficacy in treating RET fusion-positive non–small cell lung cancer (NSCLC) even after disease progression.

A recent Phase II clinical trial has revealed promising results for men with low-grade prostate cancer on active surveillance (AS).

A new AI-powered model predicts outcomes for breast cancer patients on CDK4/6 inhibitors, offering precise insights into treatment response and enabling personalized care.

In this study, patients with a recurrence scores greater than 31 exhibited significant improvements in survival outcomes when treated with taxane and anthracycline-based chemotherapy.

Findings, presented at SABCS 2024, support tamoxifen as an effective adjuvant therapy for reducing recurrence in women with “good-risk” DCIS who opt to skip RT.

Avoiding chest wall irradiation post-mastectomy is safe for most intermediate-risk breast cancer patients, improving quality of care.

A novel deep learning-based radiomic biomarker could significantly enhance prediction of response to immune checkpoint inhibitors (ICIs) in patients with advanced non-small cell lung cancer (NSCLC).

Patients with low-risk ductal carcinoma in situ (DCIS) who chose active monitoring over immediate surgery reported similar quality-of-life outcomes, according to findings from the COMET trial presented at the 2024 San Antonio Breast Cancer Symposium (SABCS).

Risk-reducing surgeries, including bilateral mastectomy (RRM) and salpingo-oophorectomy (RRSO), are associated with improved survival outcomes in BRCA-mutation carriers diagnosed with breast cancer at or before age 40, according to a study presented at the 2024 San Antonio Breast Cancer Symposium (SABCS).

Active monitoring may be a safe and effective treatment option for patients with low-risk ductal carcinoma in situ (DCIS), according to the findings of the COMET trial presented at the San Antonio Breast Cancer Symposium (SABCS) 2024.

At the 2024 San Antonio Breast Cancer Symposium (SABCS), new Phase III trial data presented the promising results of imlunestrant, an oral next-generation selective estrogen receptor degrader (SERD), in patients with advanced breast cancer.

Daily glucocorticoid hormones, commonly prescribed to reduce inflammation, can significantly influence the progression of glioblastoma (GBM), the most aggressive brain cancer in adults, according to new research.

Patients with high-risk, BRCA-positive breast cancer receiving the PARP inhibitor olaparib after standard treatment continue to experience significant survival benefits, according to 6-year follow-up results from the Phase III OlympiA trial.

Socioeconomic barriers and medical distrust hindered COVID-19 vaccine completion among cancer survivors, a high-risk group for severe outcomes from the virus, according to a recent study.

Over the past 45 years, cancer prevention and screening interventions have averted nearly 6 million deaths from major cancers in the United States, according to new research.

Emerging data highlights a critical complication for patients with metastatic lung cancer undergoing treatment with immune checkpoint inhibitors (ICIs), including PD-1 and PD-L1 blockers.

Patients with cancer vaccinated against COVID-19 within 6 months before infection showed significantly higher survival rates, according to a new analysis from the ASCO COVID-19 Registry.

Agricultural pest management methods were explored in a new study to determine how they can be adapted to combat cancer treatment resistance.

Glucose restriction in the tumor microenvironment helps cancer cells survive chemotherapy by altering key metabolic pathways, reveals a new study.

A recent analysis of the IDEAL clinical trial highlights a breakthrough for early-stage breast cancer.

Patients with multiple sclerosis (MS) may experience a slightly increased risk of developing cancer compared to the general population, according to a new nationwide French study spanning 10 years.

Mailed fecal immunochemical testing (FIT) kits using centralized outreach significantly increases colorectal cancer (CRC) screening rates in underserved communities, according to the results of a new study.

The response to tamoxifen, a cornerstone drug in preventing breast cancer recurrence, may hinge on an unexpected factor: gut bacteria.

Even healthy breast tissue harbors rare populations of mutated epithelial cells, raising important questions about their role in breast cancer development.

A randomized clinical trial has revealed that pharmacological ascorbate (high-dose intravenous vitamin C) improves survival outcomes for patients with metastatic pancreatic cancer, a disease with notoriously low 5-year survival rates.

CAR T-cell therapy, a major advancement in treating hematologic cancers, has struggled to show consistent success in solid tumors.

A new Phase III clinical trial has revealed that combining nivolumab with doxorubicin, vinblastine, and dacarbazine (N+AVD) improves progression-free survival in patients with Stage III or IV classic Hodgkin’s lymphoma compared to the standard brentuximab vedotin with AVD (BV+AVD).

A recent study has spotlighted the regulatory divide between the US Food and Drug Administration’s (FDA) Accelerated Approval (AA) pathway and the European Medicines Agency’s (EMA) Conditional Marketing Authorization (CMA) process, showing stark differences in their cancer drug approvals.

Overtreatment of prostate cancer persists among men with limited life expectancy within the Veterans Affairs (VA) health system.

A genetic variant, the BIM deletion polymorphism (BDP), has been identified by researchers to significantly enhance leukemia stem and progenitor cells’ survival, making them resistant to common targeted therapies.

A powerful link between health insurance status and racial and ethnic disparities in advanced cancer diagnoses has been identified in a recently published study.

Prognostic value of specific visceral protein ratios in patients with colon cancer can offer healthcare professionals a novel approach to estimating progression-free survival (PFS) and overall survival (OS) in affected patients.

A recent study sheds light on how estrogen signaling affects immune response in breast cancer, potentially opening pathways for combined anti-estrogen and immunotherapy approaches.

Nearly half of patients with metastatic melanoma treated with a combination of the immune checkpoint inhibitors nivolumab and ipilimumab have survived cancer-free, underscoring the impact of immunotherapy in advanced melanoma.

Duloxetine, a widely used and popular antidepressant, has been recalled by U.S. Food and Drug Administration (FDA) due to the detection of N-nitroso-duloxetine, a chemical suspected of being carcinogenic.

Diet quality could play a role in the progression of prostate cancer for men undergoing active surveillance.

The U.S. FDA has approved a wearable device for treating metastatic non-small cell lung cancer in adults. Used with PD-1/PD-L1 inhibitors or docetaxel, it showed a median survival of 13.2 months.

A new study from The University of Texas MD Anderson Cancer Center has revealed that a combination of dual immunotherapy and chemotherapy improves outcomes for patients with metastatic NSCLC who harbor specific mutations.

Breast cancer deaths have declined by 44% since 1989, but rising diagnoses and racial disparities highlight the need for targeted care and early detection.

Greater BRCA genetic testing among men has been highlighted as a critical need in a recently published review

One-third of popular social media articles about breast, colorectal, lung, and prostate cancer contained misleading or harmful information, according to a new study.

Inherited BRCA mutations may sharply increase the risk of early-onset multiple myeloma, according to new research.

Protective cells can be converted into tumor promoters after the immune system has been hijacked by cancer.

The effects of radiotherapy on patients with systemic sclerosis (SSc) who develop cancer is a subject of growing concern due to the potential exacerbation of SSc symptoms and the risks of radiotherapy-related toxicity.

A recent study by Stanford University School of Medicine, California, has uncovered a significant correlation between patients with cancer who do not opt for surgery and an elevated risk of suicide.

A recent study examining cancer incidence trends among adults born between 1920 and 1990, revealed a concerning increase in cancer rates among younger generations.

In a new study researchers have highlighted the benefit of using ultrasound to image women with high-risk of advanced invasive breast cancer.

Read the latest developments in treating synovial sarcoma, as the FDA grants accelerated approval to afamitresgene autoleucel for treatment

Research from the University of Miami Miller School of Medicine: a 10-gene biomarker that predicts the benefit of adjuvant chemotherapy for stage II and III colon cancer patients.

Best of ASCO 2024 Miami: FLOT improves survival in esophageal cancer, ctDNA guides colorectal therapy, and biomarkers show promising results.

A news article on how breast cancer can cause depression and anxiety in breast cancer survivors, and ways to treat this